Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan A Webster

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Leukemia & Lymphoma|February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary diseaseKhaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.
Leukemia Research|September 29, 2017
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemiaJonathan A Webster, Raoul Tibes, Larry Morris, et al.
Leukemia Research|September 17, 2025
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbiditiesJ Preston Claiborne, Daniel Li, Hua-Ling Tsai, et al.
Blood Neoplasia|September 15, 2025
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AMLAndrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, et al.
Biology|April 3, 2021
<i>FLT3</i>-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk StratificationAndrew Y Li, Sarah M Kashanian, Bryan C Hambley, et al.
Cell Death and Differentiation|March 28, 2024
AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell deathJia Jia, Wenbo Ji, Antoine N Saliba, et al.
Blood Cancer Discovery|November 15, 2021
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaJoshua F Zeidner, Benjamin G Vincent, Anastasia Ivanova, et al.
Cancer Research|January 8, 2021
CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute LeukemiaHusheng Ding, Nicole D Vincelette, Cordelia D McGehee, et al.
Haematologica|May 8, 2025
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapyJonathan A Webster, Madison Reed, Hua-Ling Tsai, et al.
Blood Advances|October 20, 2020
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamideJonathan A Webster, Leo Luznik, Hua-Ling Tsai, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Leukemia & Lymphoma|February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary diseaseKhaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.
Leukemia Research|September 29, 2017
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemiaJonathan A Webster, Raoul Tibes, Larry Morris, et al.
Leukemia Research|September 17, 2025
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbiditiesJ Preston Claiborne, Daniel Li, Hua-Ling Tsai, et al.
Blood Neoplasia|September 15, 2025
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AMLAndrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, et al.
Biology|April 3, 2021
<i>FLT3</i>-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk StratificationAndrew Y Li, Sarah M Kashanian, Bryan C Hambley, et al.
Cell Death and Differentiation|March 28, 2024
AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell deathJia Jia, Wenbo Ji, Antoine N Saliba, et al.
Blood Cancer Discovery|November 15, 2021
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaJoshua F Zeidner, Benjamin G Vincent, Anastasia Ivanova, et al.
Cancer Research|January 8, 2021
CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute LeukemiaHusheng Ding, Nicole D Vincelette, Cordelia D McGehee, et al.
Haematologica|May 8, 2025
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapyJonathan A Webster, Madison Reed, Hua-Ling Tsai, et al.
Blood Advances|October 20, 2020
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamideJonathan A Webster, Leo Luznik, Hua-Ling Tsai, et al.
Pageof 3